Skip to main content
. 2020 May 11;55:102779. doi: 10.1016/j.ebiom.2020.102779

Figure 1.

Figure 1

Trial participant flow chart. Intention-to-treat exposed population includes every participant receiving at least one dose of dolutegravir+lamivudine. Per protocol population excludes participants who received the therapy with protocol deviations.